The practical takeaway is that even a temporary course of retatrutide provides metabolic value beyond the weight loss itself
Retrieved from Ghusn, W., De la Rosa, A., Sacoto, D., et al
Providers are increasingly seeing side effects such as: Nausea, vomiting, and delayed gastric emptying Fatigue and muscle loss during rapid weight loss Micronutrient depletion from reduced food intake Emotional dysregulation related to appetite and blood sugar swings Plateaus or weight regain after discontinuation Some patients also feel disconnected from their hunger cues or experience anxiety about long-term dependency on injections
Summary: Retatrutide dosage for weight loss in clinical trials follows a stepwise escalation from 12 mg subcutaneously once weekly up to maintenance doses of 4 mg, 8 mg, or 12 mg, though the medicine is not yet approved for use in the UK
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
